Tuberculosis (TB) is an infectious disease caused by Mycobacterium
tuberculosis. TB is one of the top ten causes of death in the world and it is highly
prevalent, characterized by the constant occurrence of drug-resistant cases, and
confounded by the incidence of respiratory diseases caused by nontuberculous
mycobacteria (NTM). The anti-TB drugs commonly used are insufficient and have
multiple adverse effects. Therefore, a new strategy to eradicate this infectious disease is
required. The implementation of new anti-TB drugs together with host-directed therapy
(HDT) can decrease the duration of treatment and improve the TB patients’ health. It is
proposed that natural products are an enormous source of bioactive compounds to treat
TB. They can be new anti-TB drugs or agents for HDT.
Keywords: Allicin, Antimycobacterial compounds, Baicalin, α-Mangostin, Host-
Directed Therapy (HDT), Nordihydroguaiaretic acid, Pasakbumin A, Tuberculous
and nontuberculous mycobacteria, (10-15) Tuberculosis.
